{'fraction_non_alphanumeric': 0.022690437601296597, 'fraction_numerical': 0.0016207455429497568, 'mean_word_length': 5.785714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Lithium carbonate (Contemnol--Spofa). A clinical study].

The estimation of the present day stage in the therapy with lithium salts allowed the authors some considerations on the mechanisms of action and pharmacodynamics of lithium ion, as well as on the indications and counterindications, side effects and therapeutical management. Thus, the authors have analysed the findings of a simple-blind clinical study on lithium carbonate (Contemnol--Spofa) in a series of 15 inpatients. The research methodology included the thorough examination of the patients, blood lithium screening, psychological investigations and laboratory tests on the basis of an itemized investigation card. The analysis of the results confirmed the efficacy of this substance in bipolar hyperthymic psychosyndromes, depressions and hyperthymic psychosyndromes with dissociative elements, its tolerance and low incidence of side effects. The selection of the cases, the clinical and paraclinical examinations, the observance of the indications and counterindications permit the administration of this substance as a curative and prophylactic treatment, providing the blood lithium is screened and clinical control and biological investigations are carried out.